WO2006068168A1 - 医療用生分解性生体吸収材料 - Google Patents
医療用生分解性生体吸収材料Info
- Publication number
- WO2006068168A1 WO2006068168A1 PCT/JP2005/023464 JP2005023464W WO2006068168A1 WO 2006068168 A1 WO2006068168 A1 WO 2006068168A1 JP 2005023464 W JP2005023464 W JP 2005023464W WO 2006068168 A1 WO2006068168 A1 WO 2006068168A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- mol
- copolymer
- type polymer
- dmo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
Definitions
- the present invention relates to a biomedical biodegradable bioabsorbable material such as a suture thread, a vascular stent, a biological cell carrier, a drug carrier and the like.
- the present invention relates to a degradable bioabsorbable material and a method for producing the same.
- Bioabsorbable polymers used as medical materials such as vascular stents and sutures include polylactic acid, polydaricholic acid, and polydaractin, polydioxanone, polyglyconate (triglycerates), which are copolymers of both.
- a copolymer of methylene carbonate and glycolide A copolymer of methylene carbonate and glycolide).
- Such bioabsorbable polymers are widely used because they degrade in vivo and absorb force, but their mechanical properties such as tensile strength and the degradation rate for absorption are almost fixed. However, increasing its mechanical properties makes it brittle and slows its degradation rate. Further, when the decomposition rate is increased, the mechanical characteristics are decreased. Therefore, there is a problem that the purpose and place of use are limited.
- Non-Patent Document 1 Polymer Papers, Vol. 56, No. 9, pp. 550—556 (September 1999) Disclosure of Invention
- PLLA polylactic acid
- P ( L-LA / CL / DMO) see Non-Patent Document 1
- CL contributes to decomposability, but greatly reduces heat resistance and mechanical properties
- DMO is also degradable.
- it hardly contributes to heat resistance and mechanical properties.
- the degradability is short in the period required for degrading in vivo, and the better heat resistance is suitable for industrial molding. It has an appropriate glass transition temperature for maintaining various properties in the temperature and storage environment and maintaining the strength at the living body temperature, and the mechanical property means a strength high enough to function as a medical device in the living body.
- the present inventors have found that mechanical properties and thermal properties are unexpectedly improved by mixing two kinds of polymers forming a stereocomplex, so that the present invention can be completed. It came. That is, the present invention provides a biodegradable bioabsorbable material for medical use, which is a polymer blend of the following A-type polymer and B-type polymer.
- 1 2 1 2 1 2 is 50-100 mol%, m and m are 3-8, R and R are hydrogen or carbon number 1
- R and R are alkyl groups having 1 to 2 carbon atoms, R, R,
- R and R ′ are alkyl groups having 1 to 4 carbon atoms
- the ratio is preferably 1 to 20 mol%.
- Y and y are different ratios
- n 70 to 99 mol%.
- m and m may be different values.
- R and R may or may not have optical activity.
- R, R ′, R and R may be different from each other, preferably a methyl group or
- the number-average molecular weight of the A-type polymer and the B-type polymer may be different from the viewpoint of formation of a stereocomplex body.
- 1 ⁇ 10 3 to 3 ⁇ 10 5 is more preferable, and 2 ⁇ 10 3 to 3 ⁇ 10 5 is more preferable, and 2 ⁇ 10 4 to 2 ⁇ 10 5 is more preferable.
- the A-type polymer and the B-type polymer may be different from the random copolymer and the block copolymer, respectively. From the viewpoint of properties and mechanical properties, a random copolymer is preferred.
- the blend ratio of A type polymer and B type polymer is from 1: 9 to 9: 1 from the viewpoint of thermal properties and mechanical properties. Is more preferably 3: 7 to 7: 3.
- R is hydrogen or an alkyl group having 1 to 4 carbon atoms
- R is an alkyl group having 1 to 2 carbon atoms.
- R, R ′, R and R are alkyl groups having 1 to 4 carbon atoms.
- a catalyst amount required typically relatively monomer 1 0 one 7 ⁇ 10- 3 mol / mol
- a catalyst amount required typically relatively monomer 1 0 one 7 ⁇ 10- 3 mol / mol
- Commonly used polymerization catalysts include metal catalysts such as tin octylate, and higher alcohols may be added as initiators.
- the monomer, catalyst and initiator are sufficiently stirred in the reaction vessel and polymerized in the temperature range of 120 to 200 ° C under an inert gas atmosphere. The polymerization temperature, catalyst amount, and polymerization time are adjusted according to the desired molecular weight.
- the polymer After the polymerization is completed, the polymer is dissolved in an organic solvent such as black mouth form, and the polymer is purified by reprecipitation with methanol or the like.
- the catalyst at the end of the polymer can be removed by adding hydrochloric acid equimolar or more to the catalyst used to produce a metal salt.
- Polymer blending methods include L-DMOZL-LA2 copolymer and L-DMOZD-LA2 copolymer, or L-DMOZCLZL-LA3 copolymer and L-DMOZCLZD-LA3.
- the copolymer is dissolved again in an appropriate amount of black mouth form at a predetermined ratio, mixed, stirred vigorously for 1 to 3 hours, poured into a Teflon (registered trademark) petri dish, and cast into a polymer blend (stereo). (Complex).
- the polymer blend can be obtained by dissolving in chloroform and reprecipitating and purifying with methanol. The above purification removes a low molecular weight polymer that does not form a stereocomplex.
- the side chain R group as shown in the figure is hydrogen or an alkyl group having 1 to 4 carbon atoms, and the side chain R ′
- 1 1 group is an alkyl group having 1 to 2 carbon atoms.
- a depsipeptide synthesized with an amino acid and a hydroxy acid derivative is obtained by using chloroacetyl chloride, 2-bromopropiol bromide and 2-bromo-n-butyryl bromide as the hydroxy acid derivative.
- chloroacetyl chloride, 2-bromopropiol bromide and 2-bromo-n-butyryl bromide are the L-MMO, L-DMO, and L-MEMO according to the jet of the hydroxy acid derivative, respectively, and these are all applicable to the present invention ⁇ as these depsipeptide monomers and bioabsorbable polymers.
- the enzymatic degradation of the copolymer with force prolatathon (CL) is in the order of L-MMO / CL> L-DMO / CL> L-MEMO / CL in the degradation with proteinase IV.
- depsipeptides synthesized from amino acids and oxyacid derivatives use L-alanine, L- (DL- or D-) parin and L-leucine as amino acids, and the obtained depsipeptides are used in the order of amino acids.
- DMO, PMO, and BMO all of which are applicable to the present invention.
- the enzymatic degradation of copolymers of these depsipeptide monomers and ⁇ -force prolataton (CL) is not due to degradation by proteinase ⁇ .
- DMO cyclic depsipeptide
- L-LA L-lactide
- CL ⁇ -force prolataton
- FIG. 2 is a structural diagram of a copolymer having peptide units obtained by polymerizing this depsipeptide.
- U indicates depsipeptide unit! /
- Cyclic depsipeptide is a cyclic ester amide that also has ⁇ -amino acid and ⁇ -hydroxy acid derivative power.
- DL-alanine was used as the ⁇ -amino acid
- DL-2-bromopropio-bromide an a-hydroxy acid derivative
- DMO was purified by recrystallization twice from black mouth form.
- cyclic depsipeptide (L-DMO) was synthesized from an a-amino acid (L-alanine) and an a-hydroxy acid derivative (DL-2-bromopropio-bromide) and then used after purification.
- L-lactide (L-LA) was recrystallized from THF and purified by sublimation (twice).
- the copolymer was prepared as follows.
- a predetermined amount of CL monomer is put in the same polymerization vessel, and the vessel is sealed.
- the sealed vessel was immersed in a 120 ° C. oil bath to initiate polymerization.
- the polymerization vessel was removed from the oil bath and cooled.
- the amount of hydrochloric acid added to tin oxalate and stir 3 minutes or more
- the salt was extracted into distilled water (at least once), dehydrated and dried, and then purified by reprecipitation in methanol.
- Tables 1 and 2 show the yield and molecular weight of the polymers obtained.
- L-DMOZCLZD-LA ternary random copolymer L-DMOZL-LA binary random copolymer, using the same method as above, using two or three monomers to be polymerized, respectively. And L-DMOZD-LA binary random copolymer were synthesized.
- 1 H NMR data ( ⁇ , CDC1) of the obtained copolymer is shown below.
- the copolymer composition was determined by determining the peak integrated value specific force of 1 H NMR ⁇ vector measured using a 400 MHZ nuclear magnetic resonance apparatus (JEOL JMN-LA400). In addition, these spectra were also estimated for the chain arrangement (randomness) of the copolymer.
- the number average molecular weight (Mn) and molecular weight distribution (Mw / Mn) of the polymer are
- GPC8010 system ⁇ Column: TSKgel (G2000H + G3000H + G4000H + G
- the calibration curve force produced by was also determined. A black mouth form was used as the eluent, and the flow rate was 1 mL min.
- thermal properties of the polymer and polymer blend ie, glass transition temperature (Tg), melting point (Tm) and heat of fusion ( ⁇ Hm) were measured using a differential scanning calorimeter SS C5100DSC22C manufactured by Seiko Instruments Inc. The measurement was performed in a nitrogen atmosphere at a heating rate of 10 ° C / mi ⁇ .
- the mechanical properties (tensile strength and elongation at break) of the polymer and polymer blend were measured using a tensile tester AGS-H 100N manufactured by Shimadzu Corporation at a crosshead speed of 100 mm / min and a distance between the gauge points of 15 mm. . The measurement was performed at least three times and the average value was adopted.
- Polymer sample dumbbell specimens (40 mm x 40 mm x 0.2 mm) were prepared by heating and pressing a polymer material at 180 to 200 ° C for approximately 5 minutes (model SDMP-1000-D, standard JISK-7162-). 5B) Enzymatic degradation tests of polymers and polymer blends are outlined below.
- a polymer film (thickness: approx. 200 ⁇ m, several tens of g) enclosed in a polyethylene sheet mesh (mesh approx. 1 X lmm) is introduced into a sample tube bottle containing enzyme and buffer (50 ml) (37 ° C) to decompose.
- the enzyme concentration was 1 International Unit (IU) per mg of polymer sample.
- the buffer solution (decomposition solution) containing the enzyme was replaced with a new decomposition solution approximately every 40 hours in consideration of the decrease in oxygen activity and the contamination and growth of microorganisms in the air.
- Degradability was evaluated by changes in polymer weight and physical properties (molecular weight, composition, thermal properties) before and after degradation.
- proteinase K derived from Tritirachium album, manufactured by Merck & Co., Inc., enzyme activity 30.0 mAnson U / mg
- Tricine pH 8.0
- the binary copolymer and the ternary copolymer have a strong randomness because one Tg and one Tm are observed. Is suggested. In addition, it can be confirmed from the 1 H NMR spectrum of the ternary copolymer of FIGS. 5 and 6 that the terpolymer is random.
- the proton peaks (k, h) of ⁇ - and ⁇ -methylene in the CL unit are sensitive to adjacent comonomer units, and each of these peaks is split into two (k, h (The peak on the high magnetic field side corresponds to the CL-CL homo-sequence, and the peak based on the low-high magnetic field side peak force SL-LA-CL and L-DMO-CL heterosequences.)
- the terpolymer was found to be a random copolymer.
- this unit is precisely introduced into the copolymer because of its high reactivity and L-LA (Tm is about 95 ° C) polymerization occurs first, and L-DMO (and Z or CL) is ring-opened by this active growth terminal, and is also a force that is randomly incorporated into the copolymer.
- the polymer blends of the binary and terpolymers are superior to those of PLLA, the binary copolymer alone, and the terpolymer copolymer alone. Properties and thermal properties, better degradability than PLLA.
- Stereocomplex polylactic acid has a small mechanical property (elongation), and there is a restriction in terms of cracking and cracking as a medical device that deforms in the body such as expansion .
- the bioabsorbable polymer in the present invention exhibits the necessary and sufficient elongation characteristics similar to those of binary copolymers and terpolymers without sacrificing strength, thermal characteristics, decomposition characteristics, etc. Suitable for use as a tool!
- bioabsorbable polymer in the present invention is adjusted by adjusting the blend ratio thereof. It is also possible to adjust the degradability.
- the NH group of the depsipeptide unit of the bioabsorbable polymer is hydrophilic, it is a medical for in-vivo in comparison with polylactic acid (lactide), force prolatatone and their copolymers without hydrophilic groups. It has higher biological friendliness as a device or a bioabsorbable medical device.
- FIG. 1 is a structural diagram of depsipeptide.
- FIG. 2 is a structural diagram of a copolymer having a depsipeptide unit.
- FIG. 3 is a structural diagram illustrating synthesis of depsipeptide.
- FIG. 4 is a structural diagram of binary and ternary copolymers obtained by ring-opening copolymerization of depsipeptides.
- FIG. 5 is a graph showing a 1 H NMR ⁇ vector of L-DM0ZCLZL-LA terpolymer.
- FIG. 6 is a graph showing the 1 H NMR ⁇ vector of L-DMOZCLZD-LA terpolymer.
- FIG. 7 is a graph showing a 1 H NMR spectrum of L-DMOZL-LA binary copolymer.
- FIG. 8 is a graph showing a 1 H NMR spectrum of L-DMOZD-LA binary copolymer.
- FIG. 9 is a graph showing the change in strength and heat resistance according to the blend ratio of the binary copolymer.
- FIG. 10 is a graph showing changes in strength and heat resistance depending on the blend ratio of the terpolymer.
- FIG. 11 is a graph showing the results of an enzyme degradability test.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Polyesters Or Polycarbonates (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05820158A EP1832302A4 (en) | 2004-12-24 | 2005-12-21 | BIODEGRADABLE AND BIORESORBABLE MATERIAL FOR MEDICAL PURPOSES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-373964 | 2004-12-24 | ||
JP2004373964A JP2006175153A (ja) | 2004-12-24 | 2004-12-24 | 医療用生分解性生体吸収材料 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006068168A1 true WO2006068168A1 (ja) | 2006-06-29 |
Family
ID=35449162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/023464 WO2006068168A1 (ja) | 2004-12-24 | 2005-12-21 | 医療用生分解性生体吸収材料 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050271617A1 (ja) |
EP (1) | EP1832302A4 (ja) |
JP (1) | JP2006175153A (ja) |
CN (1) | CN101076362A (ja) |
WO (1) | WO2006068168A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008120887A (ja) * | 2006-11-09 | 2008-05-29 | Univ Kansai | 柔軟性生分解性ポリマー |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
JP5102200B2 (ja) * | 2006-03-30 | 2012-12-19 | テルモ株式会社 | 生体内留置物 |
WO2007116646A1 (ja) * | 2006-04-04 | 2007-10-18 | Terumo Kabushiki Kaisha | 生体内留置物 |
WO2009072172A1 (ja) | 2007-12-03 | 2009-06-11 | Goodman Co., Ltd. | ステント及びその製造方法 |
US9592044B2 (en) | 2011-02-09 | 2017-03-14 | C. R. Bard, Inc. | T-fastener suture delivery system |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11226110A (ja) * | 1998-02-12 | 1999-08-24 | Bmg:Kk | 外科用接着剤組成物 |
WO2003047646A1 (en) * | 2001-12-04 | 2003-06-12 | Inion Ltd | Resorbable polymer composition, implant and method of making implant |
WO2004000377A1 (ja) * | 2002-06-25 | 2003-12-31 | Goodman Co., Ltd | 医療用生体吸収性プラスチック製用具 |
WO2004000376A1 (ja) * | 2002-06-25 | 2003-12-31 | Goodman Co., Ltd | 医療用生分解性生体吸収材料およびその製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6136321A (ja) * | 1984-07-27 | 1986-02-21 | Daicel Chem Ind Ltd | 新規なポリマ−およびその樹脂組成物 |
JP2986860B2 (ja) * | 1990-07-03 | 1999-12-06 | グンゼ株式会社 | 骨固定用具 |
AU2831900A (en) * | 1999-02-19 | 2000-09-04 | Universiteit Utrecht | Stereocomplex hydrogels |
JP2001031762A (ja) * | 1999-07-21 | 2001-02-06 | Sharp Corp | 乳酸系生分解性重合体 |
-
2004
- 2004-12-24 JP JP2004373964A patent/JP2006175153A/ja active Pending
- 2004-12-29 US US11/025,807 patent/US20050271617A1/en not_active Abandoned
-
2005
- 2005-12-21 CN CNA200580040255XA patent/CN101076362A/zh active Pending
- 2005-12-21 EP EP05820158A patent/EP1832302A4/en not_active Withdrawn
- 2005-12-21 WO PCT/JP2005/023464 patent/WO2006068168A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11226110A (ja) * | 1998-02-12 | 1999-08-24 | Bmg:Kk | 外科用接着剤組成物 |
WO2003047646A1 (en) * | 2001-12-04 | 2003-06-12 | Inion Ltd | Resorbable polymer composition, implant and method of making implant |
WO2004000377A1 (ja) * | 2002-06-25 | 2003-12-31 | Goodman Co., Ltd | 医療用生体吸収性プラスチック製用具 |
WO2004000376A1 (ja) * | 2002-06-25 | 2003-12-31 | Goodman Co., Ltd | 医療用生分解性生体吸収材料およびその製造方法 |
Non-Patent Citations (4)
Title |
---|
DATABASE CAPLUS [online] SHIRAHAMA H.: "Characteristics of the biodegradability and physical properties of stereocomplexes between poly(L-lactide) and poly(D-lactide) copolymers.", XP003001139, accession no. STN Database accession no. (2005:54157) * |
FENG Y. ET AL.: "Lipase catalyzed copolymerization of 3(S)-isopropylmorpholine-2, 5-dione and D,L-lactide", MACROMOLECULAR BIOSCIENCE, vol. 4, no. 6, 2004, pages 587 - 590, XP003001137 * |
See also references of EP1832302A4 * |
SHIRAHAMA H. ET AL.: "Preparation and enzymatic degradation of depsipeptide/lactone/lactide terpolymers", KOBUNSHI RONBUNSHU, vol. 56, no. 9, 1999, pages 550 - 556, XP003001138 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008120887A (ja) * | 2006-11-09 | 2008-05-29 | Univ Kansai | 柔軟性生分解性ポリマー |
Also Published As
Publication number | Publication date |
---|---|
JP2006175153A (ja) | 2006-07-06 |
EP1832302A4 (en) | 2008-11-12 |
EP1832302A1 (en) | 2007-09-12 |
CN101076362A (zh) | 2007-11-21 |
US20050271617A1 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4753992B2 (ja) | 新規な温度及びpH感受性のブロック共重合体及びこれを用いた高分子ヒドロゲル | |
Choi et al. | Synthesis and characterization of elastic PLGA/PCL/PLGA tri-block copolymers | |
WO2006068168A1 (ja) | 医療用生分解性生体吸収材料 | |
CA2709967C (en) | Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof | |
EP2498835B1 (en) | Biodegradable thermoplastic elastomers | |
JP6343031B2 (ja) | 高性能高分子量ポリl−乳酸合成プロセス | |
JP2009501559A (ja) | 再吸収性ポリエーテルエステル及び医療用インプラントを製造するためのその使用 | |
JP2009019040A (ja) | ヒドロキシ酸から誘導されたモノマー及びそれから調製されたポリマー | |
JP3379841B2 (ja) | ブロック共重合ポリ(エステル−カーボネート)及びその製造方法 | |
JP2001031762A (ja) | 乳酸系生分解性重合体 | |
EP3978569A1 (en) | Polymer composition, molded body and nerve regeneration inducing tube | |
JP2016210894A (ja) | ステレオコンプレックスマルチブロック共重合体及び成形体 | |
Liu et al. | Enzyme-catalyzed degradation of poly (l-lactide)/poly (ɛ-caprolactone) diblock, triblock and four-armed copolymers | |
JP5258189B2 (ja) | 柔軟性生分解性ポリマー | |
JP2008222768A (ja) | 分岐型生分解性ポリエステル及びその製造方法 | |
Xie et al. | Synthesis and characterization of novel biotinylated biodegradable poly (ethylene glycol)-b-poly (carbonate-lactic acid) copolymers | |
Heiny et al. | Progress in functionalized biodegradable polyesters | |
Lee et al. | Synthesis and degradation behaviors of PEO/PL/PEO tri-block copolymers | |
JP4804102B2 (ja) | 反応性置換基を有する生分解性重合体 | |
JP3744800B2 (ja) | 反応性置換基を有する生分解性重合体 | |
Chen et al. | Synthesis and solubility of polylactide-co-poly (amino acid) random copolymer | |
WO2004000376A1 (ja) | 医療用生分解性生体吸収材料およびその製造方法 | |
US20050163822A1 (en) | Biodegradable bio-absorbable material for clinical practice and method for producing the same | |
CN1418901A (zh) | 含羧基聚乳酸组成物及其制备方法 | |
Watanabe et al. | Syntheses of random and block copolymers of lactides with 1, 5-dioxepan-2-one and their biodegradability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005820158 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580040255.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005820158 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |